

Remarks

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

Claims 1-19, 47, and 48 have been cancelled without prejudice. Claim 50 has been amended to depend from claim 49, and claim 49 has been amended to provide antecedent basis for the term “compound,” which is recited in several dependent claims. No new matter has been introduced. Claims 49-56 remain pending.

The rejection of claims 1, 3, 6, and 14-17 under 35 U.S.C. § 102(b) as anticipated by U.S. Patent No. 5,028,622 to Plaitakis (“Plaitakis”) is rendered moot by the cancellation of these claims without prejudice.

The rejection of claim 47 under 35 U.S.C. § 102(b) as anticipated by Meakins et al., J. Nutrition 128:720-727 (1998) is rendered moot by the cancellation of claim 47 without prejudice.

The rejection of claim 47 under 35 U.S.C. § 102(b) as anticipated by the Vitaminworld.com webpage is rendered moot by the cancellation of claim 47 without prejudice.

The rejection of claims 47 and 48 under 35 U.S.C. § 102(b) as anticipated by the www.dellis.com webpage is rendered moot by the cancellation of these claims without prejudice.

The rejection of claims 1, 3, 5, 6, and 14-19 under 35 U.S.C. § 103(a) for obviousness over Plaitakis in view of U.S. Appl. Publ. No. 2003/0144244 to Herbert and U.S. Patent No. 6,200,758 to Richardson is rendered moot by the cancellation of these claims without prejudice.

In view of all of the foregoing, applicant submits that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: August 10, 2007

/Edwin V. Merkel/
Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600